Meningococcal polysaccharide vaccine group A

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Meningococcal polysaccharide vaccine group A
Accession Number
DB13889  (DB10071)
Type
Biotech
Groups
Approved, Experimental, Investigational
Biologic Classification
Vaccines
Other vaccines
Description

Meningococcal group A polysaccharide is group-specific polysaccharide antigens extracted and purified from Neisseria meningitidis serogroup A. N. meningitidis is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup A.

Synonyms
  • Meningococcal group A polysaccharide
  • Meningococcal polysaccharide antigen group A
  • Neisseria meningitidis group A capsular polysaccharide antigen
  • Neisseria meningitidis group A polysaccharide antigen, A
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Mencevax Ac Pws 500mcg/vialMeningococcal polysaccharide vaccine group A (500 mcg) + Meningococcal polysaccharide vaccine group C (500 mcg) + Sodium chloride (5 ml)Powder, for solutionSubcutaneousGlaxosmithkline Inc1994-08-292006-06-02Canada
Mencevax Ac Pws 50mcg/vialMeningococcal polysaccharide vaccine group A (50 mcg) + Meningococcal polysaccharide vaccine group C (50 mcg) + Sodium chloride (.5 ml)Powder, for solutionSubcutaneousGlaxosmithkline Inc1992-12-312006-06-02Canada
Mencevax Ac Pws Inj 2500mcg/vialMeningococcal polysaccharide vaccine group A (2.5 mg) + Meningococcal polysaccharide vaccine group C (2.5 mg) + Sodium chloride (25 ml)Powder, for solutionSubcutaneousGlaxosmithkline Inc1992-12-312006-06-02Canada
Meningococcal Polysaccharide Vaccine Groups A & CMeningococcal polysaccharide vaccine group A (500 mcg) + Meningococcal polysaccharide vaccine group C (500 mcg)Kit; Powder, for solutionSubcutaneousAventis Pasteur Sa1998-08-132007-08-14Canada
Menomune - A/c/y/w-135 CombinedMeningococcal polysaccharide vaccine group A (50 ug/0.5mL) + Meningococcal polysaccharide vaccine group C (50 ug/0.5mL) + Meningococcal polysaccharide vaccine group W-135 (50 ug/0.5mL) + Meningococcal polysaccharide vaccine group Y (50 ug/0.5mL)SubcutaneousSanofi Pasteur Inc.1981-11-232017-09-10Us
Menomune-A/c/y/w-135Meningococcal polysaccharide vaccine group A (500 mcg) + Meningococcal polysaccharide vaccine group C (500 mcg) + Meningococcal polysaccharide vaccine group W-135 (500 mcg) + Meningococcal polysaccharide vaccine group Y (500 mcg)Powder, for solutionSubcutaneousSanofi Pasteur Limited1983-12-312017-04-05Canada
Menomune-A/c/y/w-135Meningococcal polysaccharide vaccine group A (50 mcg) + Meningococcal polysaccharide vaccine group C (50 mcg) + Meningococcal polysaccharide vaccine group W-135 (50 mcg) + Meningococcal polysaccharide vaccine group Y (50 mcg)Kit; Powder, for solutionSubcutaneousSanofi Pasteur Limited1993-10-292017-04-05Canada
Menomune-A/c/y/w-135Meningococcal polysaccharide vaccine group A (2.5 mg) + Meningococcal polysaccharide vaccine group C (2.5 mg) + Meningococcal polysaccharide vaccine group W-135 (2.5 mg) + Meningococcal polysaccharide vaccine group Y (2.5 mg)Powder, for solutionSubcutaneousAventis Pasteur Limited1998-08-132006-07-17Canada
MenveoMeningococcal polysaccharide vaccine group A (10 mcg/0.5mL) + Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine (3.3-33.3 mcg/0.5mL) + Meningococcal polysaccharide vaccine group C (5 mcg/0.5mL) + Meningococcal polysaccharide vaccine group W-135 (5 mcg/0.5mL) + Meningococcal polysaccharide vaccine group Y (5 mcg/0.5mL)Powder, for solution; SolutionIntramuscularGlaxosmithkline Inc2010-07-29Not applicableCanada
NimenrixMeningococcal polysaccharide vaccine group A (5 mcg) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (44 mcg) + Meningococcal polysaccharide vaccine group C (5 mcg) + Meningococcal polysaccharide vaccine group W-135 (5 mcg) + Meningococcal polysaccharide vaccine group Y (5 mcg)Kit; Powder, for solutionIntramuscularPfizer Canada Ulc2013-08-22Not applicableCanada
Categories
UNII
1I86B47NY4
CAS number
Not Available

Pharmacology

Indication
Not Available
Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911458
RxNav
29501
FDA label
Download (83.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingPreventionInfections, Respiratory Syncytial Virus1
1, 2Active Not RecruitingPreventionRespiratory Syncytial Virus (RSV)1
1, 2CompletedPreventionMeningococcal Disease1
2Active Not RecruitingPreventionSalmonella Typhi Infection1
2CompletedPreventionHealthy Volunteers / Meningococcal Infections1
2CompletedPreventionMeningitis / Meningococcal Infections / Meningococcal Meningitis2
2CompletedPreventionMeningococcal Disease1
2CompletedPreventionMeningococcal Disease / Meningococcal Infections1
2CompletedPreventionMeningococcal Infections3
2CompletedPreventionMeningococcal Meningitis2
2CompletedPreventionMeningococcal Meningitis, Serogroup A / Meningococcal Meningitis, Serogroup B / Meningococcal Meningitis, Serogroup C / Meningococcal Meningitis, Serogroup W / Meningococcal Meningitis, Serogroup Y1
2CompletedPreventionShigella Sonnei Infection1
2CompletedPreventionVirus Diseases1
2CompletedTreatmentRelapsing Forms of Multiple Sclerosis1
2, 3CompletedPreventionMeningococcal Meningitis1
3CompletedPreventionBacterial Infections / Neisseria Meningitidis / Virus Diseases1
3CompletedPreventionBloodstream Infections / Meningitis1
3CompletedPreventionInvasive Disease Caused by Neisseria Meningitidis Due to Serogroups A, C, W-135, Y / Meningococcal Infections1
3CompletedPreventionMeningitis / Meningococcal Infections / Meningococcal Meningitis2
3CompletedPreventionMeningococcal Disease / Meningococcal Infections2
3CompletedPreventionMeningococcal Infections7
3CompletedPreventionMeningococcal Infections / Meningococcal Serogroup A, C, W-135, Y Diseases1
3CompletedPreventionMeningococcal Infections / Meningococcal Serogroup A, C, W-135, Y Diseases / Mumps / Rubella / Rubeola / Varicella1
3CompletedPreventionMeningococcal Meningitis1
3Not Yet RecruitingPreventionMeningococcal Infections1
3RecruitingPreventionHealthy Volunteers (Meningococcal Infection)2
3RecruitingPreventionMeningococcal Infections2
3SuspendedPreventionMeningococcal Infection (Healthy Volunteers)1
4Active Not RecruitingPreventionPapillomavirus Infections1
4CompletedBasic ScienceBloodstream Infections / Meningitis / Meningococcal Disease1
4CompletedPreventionDiphtheria / Meningococcal / Pertussis Diseases / Streptococcal / Tetanus1
4CompletedPreventionMeningococcal Disease1
4CompletedTreatmentImmunizations / Meningitis / Pertussis / Preventive Immunization; Meningitis1
4RecruitingOtherHuman Immunodeficiency Virus (HIV) Infections / Meningococcal Meningitis1
4RecruitingOtherMeningococcal Meningitis1
4RecruitingPreventionMeningococcal Disease, Invasive1
Not AvailableActive Not RecruitingBasic ScienceHealthy Volunteers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Powder, for solutionSubcutaneous
Kit; powder, for solutionSubcutaneous
Powder, for solution; solutionIntramuscular
Kit; powder, for solutionIntramuscular
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on September 08, 2017 14:22 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates